Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Preventive Effects of Evista on Bone Fractures in Osteoporosis Reported
June 17, 2002
- We Are at Exciting Crossroads in History: Mr Hassan at PhRMA
June 17, 2002
- Matsumotokiyoshi: Record-high Sales of \256 Bil., Profits of \6.6 Bil. Posted
June 17, 2002
- Eli Lilly's Teriparatide Effective against Severe Osteoporosis
June 17, 2002
- 94 Drugs in Development for Children: PhRMA Survey
June 17, 2002
- BULLETIN
June 17, 2002
- Ohki: Consolidated Sales Increase by 4.1% to \69.7 Bil.
June 17, 2002
- Clinical Trial Results for Eli Lilly's New ED Drug Reported
June 17, 2002
- GSK Publishes Review of Its Commitment to Society, Environment
June 17, 2002
- BUSINESS NEWS IN BRIEF
June 17, 2002
- OTC NEW IN BRIEF
June 17, 2002
- Taxotere-based Chemotherapy Improves Breast Cancer Survival
June 17, 2002
- Lilly's Drotrecogin Prolongs Survival of Severe Sepsis Patients
June 17, 2002
- Website NEWS
June 17, 2002
- Hitachi Medical to Commercialize Regenerative Tooth
June 17, 2002
- Zoledronate Effective against Bone Metastases from Prostate Cancer
June 17, 2002
- Quality of Pharmacoeconomic Research Poor: GL Needed
June 17, 2002
- Sendai Citizens' Demand Rejected: Suit over Withdrawn Drugs
June 17, 2002
- Kodak: Interfaces for Medical Image Networks
June 17, 2002
- Major Wholesalers Post Double-digit Rises in Sales, Profits
June 17, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…